How quickly does retatrutide start working?
Retatrutide users typically notice reduced appetite within 1–2 weeks. Measurable weight loss by weeks 3–4. Phase 2 data shows the curve by timepoint.
Updated May 22, 2026 · 5 min read
Most people notice reduced appetite within the first 1–2 weeks of starting retatrutide. Measurable weight loss on the scale typically begins by weeks 3–4, once the drug has accumulated toward steady-state concentration. But the full effect — meaningful percentage body weight loss — builds over months, not days.
Here's what the Phase 2 data actually shows by timepoint.
The Phase 2 Curve by Week
The Jastreboff et al. Phase 2 trial published in the New England Journal of Medicine (2023) provides the most granular timeline available for retatrutide's weight-loss curve. Participants were titrated from 1 mg up to their assigned maximum dose. Results at the 12 mg dose arm (the highest studied):
| Timepoint | Approximate mean weight loss |
|---|---|
| Week 4 | ~2–3% |
| Week 8 | ~5–6% |
| Week 12 | ~8–10% |
| Week 24 | ~15–17% |
| Week 36 | ~20–22% |
| Week 48 | ~24% |
These are approximate values from the published curves. The key observation: the curve is still descending at 48 weeks at the 12 mg dose — there's no clear plateau at the trial endpoint. For more on what that means for the drug's efficacy ceiling, see retatrutide's weight-loss curve.
Lower doses (4 mg, 8 mg) show earlier plateaus and lower total loss — the dose-response relationship is steep.
Week 1–2: Appetite and Food Noise
The first things most people on retatrutide notice are the central effects: food noise decreases, meal portions that used to feel necessary now feel like too much, and the pull toward snacking weakens. This isn't dramatic immediately — it builds over the first 1–2 weeks as the drug accumulates toward its initial steady state.
GI side effects (nausea, occasional reflux, constipation) tend to appear in this window too, often peaking in weeks 2–3 of each new dose level. The appetite suppression and the side effects are both products of the same receptor engagement.
Week 3–8: First Weight on the Scale
Measurable weight loss typically appears by weeks 3–4. In the Phase 2 cohort, the 2–3% at week 4 translates to approximately 4–6 lbs for someone starting at 180 lbs, or 6–9 lbs for someone starting at 250 lbs.
This early phase is dominated by:
- Reduced caloric intake from appetite suppression
- Possible glycogen depletion (glycogen is stored with water; early weight loss often includes some water weight)
- Slower gastric emptying, which reduces meal frequency and portion size naturally
The week-to-week variation is high early on — your weight may not move for a few days and then drop noticeably. Weekly averages are more meaningful than daily numbers in this phase.
Months 2–6: The Productive Window
Months 2–6 at maintenance dose (or at higher titration steps) are typically when the most rapid absolute weight loss occurs. The curve is steepest here because the gap between the body's energy intake and energy expenditure is widest — drug effects are strong, metabolic compensation hasn't fully set in.
At 6 months on the 12 mg dose arm of the Phase 2, mean loss was approximately 15–17%. For someone starting at 220 lbs, that's roughly 33–37 lbs.
This is also the window where people experience the most GI side effect turbulence, since each titration step involves a new 4-week accumulation toward steady state. The side effect pattern and the efficacy pattern share a timeline — see retatrutide pharmacokinetics for why each new dose takes about 4 weeks to stabilize.
Month 6 Onward: Continued Loss, Slower Rate
After month 6, weight loss typically continues but slows. The body is adapting to the lower energy intake by reducing energy expenditure — a predictable metabolic response to sustained weight loss regardless of how it was achieved.
In the retatrutide Phase 2, this shows up as the curve becoming less steep after week 24 but not flattening. At the 12 mg dose, people were still losing at week 36 and week 48, just more slowly than in the earlier months.
The TRIUMPH Phase 3 program confirms this general pattern at scale.
Retatrutide vs. Semaglutide and Tirzepatide: Onset Timing
All three drugs work through similar GLP-1 receptor mechanisms, so onset timing is broadly similar in the first weeks:
| Drug | Appetite effect onset | Scale movement | Peak loss achieved |
|---|---|---|---|
| Semaglutide | Week 1–2 | Week 3–4 | ~Weeks 52–60 (STEP-1) |
| Tirzepatide | Week 1–2 | Week 3–4 | ~Weeks 52–60 (SURMOUNT-1) |
| Retatrutide | Week 1–2 | Week 3–4 | > 48 weeks (still declining) |
The meaningful difference isn't how quickly retatrutide starts — it's how far it goes and how long it continues. The cross-trial comparison with caveats is covered in retatrutide vs tirzepatide.
Managing Early Expectations
The most common source of discouragement in the first 4–6 weeks is expecting semaglutide- or tirzepatide-speed results and being surprised when they're similar. Early-phase retatrutide and early-phase semaglutide look about the same on the scale. The difference compounds over months, not weeks.
If you're not seeing any movement by week 4–6 (not even a few pounds), it's worth checking:
- Whether you're actually at therapeutic dose or still in early titration
- Whether caloric intake has genuinely decreased (not eating less because appetite is down doesn't guarantee you're eating less if compensatory eating is happening)
- Whether something else is affecting weight (fluid retention, medications, sleep)
For week-by-week expectations across all GLP-1s, weight-loss timeline by month is useful context.